(Q44745256)

5 December 2017

title

Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion (English)

1 reference

5 December 2017

1 reference

1 reference

Bin Peng

1

1 reference

5 December 2017

Catherine Dutreix

2

1 reference

5 December 2017

Gunther Mehring

3

1 reference

5 December 2017

Michael J Hayes

4

1 reference

5 December 2017

Monique Ben-Am

5

1 reference

5 December 2017

Michael Seiberling

6

1 reference

5 December 2017

Rolf Pokorny

7

1 reference

5 December 2017

Renaud Capdeville

8

1 reference

5 December 2017

Peter Lloyd

9

1 reference

5 December 2017

publication date

1 February 2004

1 reference

The Journal of Clinical Pharmacology

5 December 2017

published in

1 reference

5 December 2017

volume

44

1 reference

5 December 2017

issue

2

1 reference

5 December 2017

page(s)

158-162

1 reference

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270003262101

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003262101

Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003262101

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003262101

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003262101

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003262101

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003262101

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003262101

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003262101

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003262101

Imatinib mesylate--the new gold standard for treatment of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003262101

Quantification of the anti-leukemia drug STI571 (Gleevec) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003262101

Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003262101

21 January 2018

Identifiers

DOI

10.1177/0091270003262101

1 reference

5 December 2017

1 reference